Skip to main content
. 2015 Aug 5;10(8):e0134842. doi: 10.1371/journal.pone.0134842

Fig 3. Functional evaluation of PPARγ in immortalized HBECs.

Fig 3

(A) PPARγ and COX2 mRNA expression was measured using QPCR assay in HBEC lines with or without troglitazone treatment. (B) Immunoblots using antibodies against COX2, cyclin D1, PPARγ or beta-actin were used to measure the corresponding protein expression in the HBEC panel when treated or not treated with 1 μM of troglitazone. (C) Growth response of HBEC-KT cell lines to the combined treatment of PPARγ ligand troglitazone (3 μM) and RXR ligand LG268 (100 nM). Data represent the mean ± SD (n = 3). Asterisks show statistically significant points as evaluated by ANOVA. *P < 0.05, **P < 0.01 and ***P < 0.001 compared to HBEC-KT control, ### P < 0.001 compared to K-rasV12 control, +++ P < 0.001 compared to K-rasV12+p53shRNA control.